Show simple item record

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

dc.contributor.authorLaud, Peter J.
dc.contributor.authorPaz-Ares, Luis
dc.contributor.authorPatel, Nikunj
dc.contributor.authorShire, Norah
dc.contributor.authorJiang, Haiyi
dc.contributor.authorGoldman, Jonathan W.
dc.contributor.authorGarassino, Marina Chiara
dc.contributor.authorChen, Yuanbin
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorDvorkin, Mikhail
dc.contributor.authorTrukhin, Dmytro
dc.contributor.authorStatsenko, Galina
dc.contributor.authorHotta, Katsuyuki
dc.contributor.authorJi, Jun Ho
dc.contributor.authorHochmair, Maximilian J.
dc.contributor.authorVoitko, Oleksandr
dc.contributor.authorHavel, Libor
dc.contributor.authorPoltoratskiy, Artem
dc.contributor.authorLosonczy, Gyorgy
dc.contributor.authorReinmuth, Niels
dc.date.accessioned2021-03-06T10:32:47Z
dc.date.available2021-03-06T10:32:47Z
dc.identifier.citationGoldman J. W. , Garassino M. C. , Chen Y., ÖZGÜROĞLU M., Dvorkin M., Trukhin D., Statsenko G., Hotta K., Ji J. H. , Hochmair M. J. , et al., "Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study", LUNG CANCER, cilt.149, ss.46-52, 2020
dc.identifier.issn0169-5002
dc.identifier.othervv_1032021
dc.identifier.otherav_ead4a624-9b18-4acd-8311-5934ca3ce492
dc.identifier.urihttp://hdl.handle.net/20.500.12627/154252
dc.identifier.urihttps://doi.org/10.1016/j.lungcan.2020.09.003
dc.description.abstractObjectives: In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall survival (primary endpoint) versus EP alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) at the interim analysis. Here we report patient-reported outcomes (PROs).
dc.language.isoeng
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectSOLUNUM SİSTEMİ
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.titlePatient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study
dc.typeMakale
dc.relation.journalLUNG CANCER
dc.contributor.departmentDavid Geffen School of Medicine at UCLA , ,
dc.identifier.volume149
dc.identifier.startpage46
dc.identifier.endpage52
dc.contributor.firstauthorID2288239


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record